{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2016"],"data_sharing_plan":["IPD Sharing (as of April 2016): Undecided"],"condition":["Colorectal Neoplasms"],"disease":["Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2213351"],"location":["China"],"study_start_month":["1"],"keyword":["Vascular Endothelial Growth Factor A","Endostar","Endostar protein","Anti-angiogenesis Drugs","Endostatins","Thalidomide","Advanced Colorectal Cancer"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical","description":"The purpose of this study is to determine whether Endostar pumping into vein with Thalidomide are more effective in the treatment of Advanced Colorectal Cancer (ACRC).","dates":{"creation":"2016-01-15"},"accession":"2213351","cross_references":{"ClinicalTrials___gov":["NCT02748772"]}}